Absorption and Elimination of Bismuth from Oral Doses of Tripotassium Dicitrato Bismuthate

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1989 Jan 1

PMID 2598996

Citations 6

Authors

P R Froomes

A T Wan

A C Keech

J J McNeil

A J McLean

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetics of bismuth subcitrate were studied in plasma and urine under conditions of single and multiple dosing (28-56 days) using atomic absorption technique. Single dose plasma pharmacokinetics showed peak concentrations of 5.5-57.5 micrograms.l-1 (mean = 24.7 micrograms.l-1), reached between 30 and 60 min post dosing with an apparent biphasic elimination pattern. Multiple dose studies showed a continuing rise in plasma concentration and urine excretion rate reaching apparent steady-state levels over 7-29 days (mean = 18 days). Washout studies in 6 individuals reciprocated accumulation. Maximum equilibrated plasma levels of 7.6-58.3 micrograms.l-1 (mean = 38.3 micrograms.l-1) were well below those associated with encephalopathy. The half-life of bismuth elimination was 20.7 days. Present patterns of intermittent dosing with bismuth are unlikely to be associated with bismuth accumulation despite slow accumulation and elimination.

Citing Articles

Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.

Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Megraud F Drug Saf. 2019; 42(8):993-1003.

PMID: 31069703 DOI: 10.1007/s40264-019-00821-6.

Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Klotz U Clin Pharmacokinet. 2000; 38(3):243-70.

PMID: 10749519 DOI: 10.2165/00003088-200038030-00004.

A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Hackelsberger A, Malfertheiner P Drug Saf. 1996; 15(1):30-52.

PMID: 8862962 DOI: 10.2165/00002018-199615010-00003.

Systemic chemotherapy for Helicobacter pylori eradication?.

Islam S, McLean A Gut. 1990; 31(12):1421-2.

PMID: 2265791 PMC: 1378778. DOI: 10.1136/gut.31.12.1421-b.

Anomalous short plasma elimination half life in a patient intoxicated with bismuth subcitrate.

McLean A, Islam S, Lambert J Gut. 1990; 31(9):1086.

PMID: 2210458 PMC: 1378677. DOI: 10.1136/gut.31.9.1086.

References

Loiseau P, Henry P, Jallon P, Legroux M . [Iatrogenic myoclonic encephalopathies caused by bismuth salts]. J Neurol Sci. 1976; 27(2):133-43. DOI: 10.1016/0022-510x(76)90056-3. View

Bianchi Porro G, Lazzaroni M, Petrillo M, DE NICOLA C . Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine. Lancet. 1984; 2(8404):698. DOI: 10.1016/s0140-6736(84)91258-3. View

Lee F, SAMLOFF I, Hardman M . Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985; 1(8441):1299-302. DOI: 10.1016/s0140-6736(85)92793-x. View

Miller J, Faragher E . Relapse of duodenal ulcer: does it matter which drug is used in initial treatment?. Br Med J (Clin Res Ed). 1986; 293(6555):1117-8. PMC: 1341843. DOI: 10.1136/bmj.293.6555.1117. View

Gaucher A, Netter P, Faure G, Hutin M, Burnel D . Bismuth-induced osteoarthropathies. Med J Aust. 1979; 1(4):129-30. DOI: 10.5694/j.1326-5377.1979.tb112060.x. View

Lee S . Studies on the absorption and excretion of tripotassium dicitrato-bismuthate in man. Res Commun Chem Pathol Pharmacol. 1981; 34(2):359-64. View

McLean A, Harrison P, Byrne A, McCarthy P, DUDLEY F . The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust N Z J Med. 1985; 15(3):367-74. DOI: 10.1111/j.1445-5994.1985.tb04065.x. View

Froomes P, Wan A, Harrison P, McLean A . Improved assay for bismuth in biological samples by atomic absorption spectrophotometry with hydride generation. Clin Chem. 1988; 34(2):382-4. View

Monseu G, Struelens M, Roland M . Bismuth encephalopathy. Acta Neurol Belg. 1976; 76(5-6):301-8. View

10.

McLean A, Harcourt D, McNeil J . Relapse rate as a major determinant of drug selection in peptic ulcer therapy. Drugs. 1988; 35(4):329-33. DOI: 10.2165/00003495-198835040-00001. View

11.

Boiteau H, Cler J, Mathe J, Delobel R, FEVE J . [The relationship between the course of bismuth encephalopathy and the amount of bismuth in blood and urine]. Eur J Toxicol Environ Hyg. 1976; 9(4):233-9. View

12.

Pieri F, Wegmann R . [Pharmacokinetic study of 205-206 Bi-citrate in the rat. Compartmental repartition (author's transl)]. Cell Mol Biol Incl Cyto Enzymol. 1981; 27(1):57-60. View

13.

McLean A, Harcourt D, McCarthy P, DUDLEY F, McNeil J . Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing. Med J Aust. 1987; 146(8):431-3, 436-8, 442. DOI: 10.5694/j.1326-5377.1987.tb120338.x. View

14.

McNulty C, Gearty J, Crump B, Davis M, Donovan I, Melikian V . Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed). 1986; 293(6548):645-9. PMC: 1341508. DOI: 10.1136/bmj.293.6548.645. View

15.

Sicard C, Risvegliato M, RANCUREL G, BUGE A . Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patients. J Neurol Neurosurg Psychiatry. 1977; 40(8):748-52. PMC: 492829. DOI: 10.1136/jnnp.40.8.748. View

16.

Martin D, Hollanders D, May S, Ravenscroft M, Tweedle D, Miller J . Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet. 1981; 1(8210):7-10. DOI: 10.1016/s0140-6736(81)90114-8. View